49. Porter, A. G., Barber, C., Carey, N. H., Hallewell, R. A., Threlfall, G. and Emtage, J. S. (1976) *Nature* (London) 282, 471–477.

50. Gething, M. J., Bye, J., Skehel, J. and Waterfield, M. (1980) *Nature* (London) 301–306.

51. Sueda, M. M. and Lai, C. J. (1981) *Proc. Natl. Acad. Sci. USA* 78, 5488–5492.

52. Gething, M. J. and Sambrook, J. (1981) *Nature* (London) 293, 620–625.

53. Davis, A. R., Bos, T., Ueda, M., Nayak, D. P., Dowbenko, D. and Compans, R. W. (1983) *Gene 21,* 273–284.

54. Smith, G. L., Murphy, B. R. and Moss, B. (1983) *Proc. Natl. Acad. Sci. USA* 80, 7155–71.

55. Novick, P., Field, C. and Schekman, R. (1980) *Cell* 21, 205–215.

56. Novick, P., Ferro, S. and Schekman, R. (1983) *Cell* 25, 461–469.

57. Wilson, I. A., Shekel, J. J. and Wiley, (1981) D. C. *Nature* 289, 366–372.

58. Colman, P. M., Varghese, J. N., and Laver, W. G. (1983) *Nature* (London) 303, 41–44.

What is claimed is:

1. A glycosylated polypeptide of human or animal influenza hemagglutinin protein comprising an amino acid sequence selected from the HA**1** or HA**2** segment of the hemagglutinin protein wherein said amino acid sequence includes at least one antigenic determinant of said hemagglutinin protein, said amino acid sequence including one or more glycosyl groups consisting essentially of high mannose sugars produced in yeast.

2. The glycosylated polypeptide according to claim **1** wherein said glycosylated polypeptide is microbially produced by *S. cerevisiae.*

3. A glycosylated polypeptide according to claim **1** wherein said amino acid sequence is selected from the amino acid sequence corresponding to the HA**1** segment of human influenza.

4. A vaccine for use in treating human and animal influenza comprising a glycosylated polypeptide according to claim **1** in admixture with a pharmaceutically acceptable carrier.

5. A vaccine according to claim **4** wherein said amino acid sequence comprises the amino acids corresponding to the HAI and HA**2** segments of the hemaglutinin protein.

* * * * *